The effect of additional acarbose on metformin-associated artificially high 18F-Fluorodeoxyglucose uptake in positron emission tomography/computed tomography

• Published in: Acta diabetologica 2022-07, Vol.59 (7), p.929-937
• Main Authors: Urhan, Emre, Temizer, Emre, Karaca, Zuleyha, Abdulrezzak, Ummuhan, Kara, Canan Sehit, Hacioglu, Aysa, Unluhizarci, Kursad
• Format: Article
• Language: English
• Subjects: Acarbose; Antidiabetics; Colon; Computed tomography; Diabetes; Diabetes mellitus; Internal Medicine; Medicine; Medicine & Public Health; Metabolic Diseases; Metformin; Nuclear medicine; Original Article; Patients; Positron emission tomography; Small intestine; Tomography
• ISSN: 1432-5233; 0940-5429; 1432-5233
• DOI: 10.1007/s00592-022-01890-3

Aim Metformin causes diffuse and intense fluorodeoxyglucose (FDG) uptake more frequently in the colon and less frequently in the small intestine. In this study, we aimed to investigate the effect of simultaneous use of acarbose and metformin on FDG uptake in positron emission tomography/computed tomography (PET/CT), which has not been investigated previously. Methods Totally 145 patients with a median age of 65 years (range: 18–80 years), who underwent FDG PET/CT in the Department of Nuclear Medicine of Erciyes University Medical School between 2018 and 2021, were involved in the study. The patients undergoing PET/CT were categorized as metformin plus acarbose users (group MA), metformin users (group M), and control subjects without diabetes (group C). The maximum and mean standard uptake values (SUVmax and SUVmean) of FDG uptake of the all intestine segments were measured separately. Results The number of participants in each group was 35, 51 and 59 in group MA, group M and group C, respectively. The FDG uptake of all intestine was significantly higher in group MA and group M than in group C. The FDG uptake of ascending, transverse, descending, and sigmoid colon was significantly lower in group MA than in group M. The FDG uptake of the small intestine was not different between group MA and group M. The FDG uptake of the rectum was lower in group MA than group M and it was significant for SUVmean, but not significant for SUVmax. Conclusion The addition of acarbose to metformin therapy decreased SUV and artificially high FDG uptake in the colon and may be an alternative recommendation to discontinuing metformin in patients going to PET/CT imaging.